20:30 , Oct 9, 2018 |  BC Extra  |  Clinical News

Affimed sinks after placing clinical hold on bispecific T cell engager

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Tuesday after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The product...
07:00 , Sep 3, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Markers for differential diagnosis of mucinous and non-mucinous pancreatic cysts

Biomarkers TECHNOLOGY: Proteomics Four proteins - afamin (AFM) , lipocalin ( NGAL ; LCN2 ), polymeric immunoglobulin receptor (PIGR) and regenerating islet-derived 1 α ( REG1A ) - could help differentially diagnose mucinous and non-mucinous...
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Atomic force microscopy (AFM) for measuring GPCR-ligand binding in lipid membranes

Assays and screens TECHNOLOGY: Binding assays An AFM-based method could measure binding affinities between ligands and GPCRs in lipid membranes. The method involves attaching a GPCR ligand to the tip of an oscillating cantilever moving...
07:00 , Jun 15, 2015 |  BioCentury  |  Emerging Company Profile

Freshening the gene pool

Horama S.A.S. is developing two gene therapies that target mutations no other companies are working on as a way of differentiating itself from the growing fraternity of ophthalmic gene therapy companies. The company was founded...
04:39 , Jan 17, 2015 |  BC Extra  |  Top Story

Roche buys neuromuscular play Trophos

Roche (SIX:ROG; OTCQX:RHHBY) acquired neuromuscular disease play Trophos S.A. (Marseille, France) for EUR 120 million ($141.8 million) in upfront cash. Trophos shareholders are eligible for up to EUR 350 million ($413.6 million) in milestones. Last...
07:00 , May 27, 2013 |  BC Week In Review  |  Financial News

AFM-Telethon, Fonds National d'Amorcage financial update

The French government's Fonds National d'Amorcage and the not-for-profit AFM-Telethon launched a seed fund to invest in biotherapeutics for rare diseases. The new fund, which will be managed by CDC Enterprises launched with €50 million...
00:01 , May 22, 2013 |  BC Extra  |  Financial News

France launches rare disease fund

The French government's Fonds National d'Amorcage and the not-for-profit AFM-Telethon launched a seed fund to invest in biotherapeutics for rare diseases. The new fund, which will be managed by CDC Enterprises launched with EUR 50...
07:00 , Jun 20, 2005 |  BioCentury  |  Strategy

Refinancing for focus

Last December, Philippe Archinard was brought in as CEO to sort out Transgene S.A. by the Merieux family, which owns 70% of the company. At the time, Transgene, which has been around since 1979, was...
08:00 , Mar 11, 2002 |  BioCentury  |  Emerging Company Profile

Corporte Profile

Gene-IT SA Rueil Malmaison, France Technology: Bioinformatics Disease focus: NA Clinical status: NA Founded: 1998 by Jean-Jacques Codani and Eric Glémet Corporate partners : BioMérieux SA, Derwent Ltd., DuPont de Nemours, NV Organon , Pfizer...
07:00 , Jul 3, 2000 |  BC Week In Review  |  Company News

Harvard University other research news

Harvard researchers and colleagues published in Nature Biotechnology the use of SWNT probes to directly visualize labeled oligonucleotides hybridized to individual DNA molecules using AFM. The researchers used conditions under which the oligonucleotides would not...